- Home
- CFBK vs NVCT Comparison
CFBK vs NVCT Comparison
Compare CFBK & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFBK
- NVCT
- Stock Information
- Founded
- CFBK 1892
- NVCT 2020
- Country
- CFBK United States
- NVCT United States
- Employees
- CFBK N/A
- NVCT N/A
- Industry
- CFBK Major Banks
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- CFBK Finance
- NVCT Health Care
- Exchange
- CFBK Nasdaq
- NVCT Nasdaq
- Market Cap
- CFBK 159.5M
- NVCT 167.0M
- IPO Year
- CFBK 1998
- NVCT 2022
- Fundamental
- Price
- CFBK $24.12
- NVCT $6.22
- Analyst Decision
- CFBK Buy
- NVCT Strong Buy
- Analyst Count
- CFBK 1
- NVCT 3
- Target Price
- CFBK $29.00
- NVCT $15.33
- AVG Volume (30 Days)
- CFBK 32.8K
- NVCT 81.0K
- Earning Date
- CFBK 10-29-2025
- NVCT 11-04-2025
- Dividend Yield
- CFBK 1.32%
- NVCT N/A
- EPS Growth
- CFBK 36.66
- NVCT N/A
- EPS
- CFBK 2.77
- NVCT N/A
- Revenue
- CFBK $52,793,000.00
- NVCT N/A
- Revenue This Year
- CFBK $39.98
- NVCT N/A
- Revenue Next Year
- CFBK $10.47
- NVCT N/A
- P/E Ratio
- CFBK $8.73
- NVCT N/A
- Revenue Growth
- CFBK 20.91
- NVCT N/A
- 52 Week Low
- CFBK $19.23
- NVCT $4.44
- 52 Week High
- CFBK $31.17
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- CFBK 47.27
- NVCT 45.15
- Support Level
- CFBK $23.65
- NVCT $5.95
- Resistance Level
- CFBK $24.44
- NVCT $6.21
- Average True Range (ATR)
- CFBK 0.37
- NVCT 0.26
- MACD
- CFBK -0.05
- NVCT 0.03
- Stochastic Oscillator
- CFBK 38.16
- NVCT 51.94
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.